Responses

Download PDFPDF
Serum IgG2 and tissue IgG2 plasma cell elevation in orbital IgG4-related disease (IgG4-RD): Potential use in IgG4-RD assessment.
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Spurious elevations in serum IgG2 may be seen by immunonephelometry in IgG4-RD - response to Chan et al [1]
    • Andre Mattman, Medical Biochemist Dept of Pathology and Laboratory Medicine, St Paul’s Hospital
    • Other Contributors:
      • Jessica Grace van der Gugten, Laboratory Scientist
      • Mari L DeMarco, Clinical Chemist
      • Mollie Carruthers, Rheumatologist
      • Alex Chin, Clinical Chemist
      • Luke YC Chen, Hematologist
      • Daniel T Holmes, Medical Biochemist

    Chan et al report on marked elevations in serum IgG2 that are observed in patients with orbital IgG4 related disease (IgG4-RD), with or without systemic involvement.

    Using ROC area under the curve comparisons, the authors show that the serum IgG2 concentration has a higher AUC (0.9) than serum IgG4 (0.8) in detecting IgG4-RD in their cohort (comprised of 33 subjects: 20 with orbital IgG4-RD with or without systemic involvement, and 13 with non-IgG4-RD orbital inflammation).

    Our group has noted this paper by Chan et al with interest as we have observed the same phenomenon of marked serum IgG2 elevations in patients with IgG4-RD, who have concomitantly low serum IgG4 concentrations. Like the patients presented by Chan et al, our IgG4-RD patients uniformly had serum IgG2 concentrations that were greater than the serum IgG4 concentration, even when the serum IgG4 concentration was very high.

    Our interpretation of the apparent superior clinical utility of the serum IgG2 test in this context, is that this observation is only made when using an immunonephelometric methodology subject to two different types of analytical error:
    i) antigen excess, leading to falsely low serum IgG4 measurement in a patient who in fact has a marked elevation of serum IgG4 [2] and
    ii) cross reactivity of the reagent used to measure IgG2 with serum IgG4, leading to falsely high serum IgG2 measurement (this may be due to a direct and specific recognition of IgG4 epitop...

    Show More
    Conflict of Interest:
    None declared.